iCardiac (Rochester) Announces Award of a Global Phase III Cardiac Safety Study (10/21/2010)

iCardiac Technologies develops and markets drug safety technology, which was originally developed at the University of Rochester Heart Research Follow-Up Program under Dr. Jean-Philippe Couderc, who is the company’s CTO.

iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced today that it has been awarded a centralized ECG services contract for a global multi-site Phase III study. The study will be conducted leveraging iCardiac’s next generation solutions for cost-effective centralization of digital ECG data as well as COMPAS technology platform for ECG data analysis. read more


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: